BIG-IV is administered intravenously, typically in a hospital setting. The dosage is calculated based on the infant's weight, and the infusion is monitored closely to manage any potential adverse reactions. The treatment is generally well-tolerated, but healthcare providers remain vigilant for possible side effects.